Zonkatron

Zonkatron’s Prediction

The obesity problem won’t ever have a pill to fully eliminate it!

Even after 50 years, even when Ozempic becomes cheap and accessible to everyone and even when pharmacology invents new drugs, it’s never going to eliminate more than 15% of the obese population.

Analysis

To understand why these medications aren’t a total “cure-all,” we have to look at how we’ve handled medical breakthroughs in the past. Take the discovery of antibiotics. When penicillin became widely available, many thought infectious diseases would be a thing of the past. But history showed us that bacteria evolve, and more importantly, the conditions that breed infection—like poor sanitation and overcrowding—don’t just disappear because we have a pill. Obesity is similar; it is a symptom of a much larger environmental “infection.”

Think of GLP-1 drugs like Semaglutide as a very sophisticated thermostat. If your house is freezing because the windows are broken and the door is wide open, the thermostat can work overtime to pump in heat. You might feel warm for a while, but the moment the power goes out or you can’t afford the electric bill, the house freezes again. The “broken windows” are our modern lifestyle: constant stress, lack of movement, and a food industry that designs snacks to be as addictive as possible.

History Tells the Truth

​We can look at the story of the Pima Indians in Arizona as a tragic case study in environment versus biology. For centuries, they were lean and healthy. But when their traditional diet was replaced by government-issued rations of white flour, lard, and sugar, obesity rates skyrocketed. A GLP-1 drug might help an individual Pima person lose weight, but it doesn’t return the river water to their farms or remove the processed food from their local stores. The medicine treats the person, but it doesn’t treat the neighborhood.

​There is also the heavy burden of biological adaptation. Our bodies are evolved to survive famines that lasted for months. When you use a drug to lose weight rapidly, your body doesn’t realize you’re doing it on purpose; it thinks you are starving. It begins to lower your body temperature and makes you more lethargic to save energy. This is why people “plateau.” Even on the strongest dose of a drug, your ancient DNA is fighting back, trying to keep you at your highest previous weight to “save” you from what it perceives as a crisis.

Consider the “anecdote of the office worker.” Let’s call him Dave. Dave starts a GLP-1 and loses 50 pounds. He feels great, but his job still requires him to sit for 10 hours a day. His commute is two hours of stressful driving. When he gets home, he’s too exhausted to cook, so he grabs a “healthy” pre-packaged meal that is actually full of preservatives. The drug is fighting a lonely battle against Dave’s entire reality. If Dave loses his insurance and can’t pay the $1,000 monthly bill, his appetite returns with a vengeance, often leading to him gaining back 60 pounds instead of 50.

Blood Pressure Analogy?

​Historically, we have seen this with blood pressure medication. We have incredible drugs to lower hypertension, yet heart disease remains a leading killer. Why? Because it’s easier to take a pill than it is to fix a food system that puts hidden salt in everything from bread to chicken breast. We become reliant on the “chemical fix” while the underlying cause—our diet—stays exactly the same. The GLP-1s are a more powerful version of this cycle.

​Another major hurdle is muscle wasting. When people lose weight on these drugs, they don’t just lose fat; they lose a significant amount of skeletal muscle. Think of muscle as the “engine” of your metabolism. If you lose your engine, you can’t burn fuel efficiently. There are stories of elderly patients becoming “skinny-fat”—they weigh less, but they are now too weak to climb stairs. Without the muscle to maintain their metabolism, they become permanently dependent on the drug just to stay at their new weight.

We must also talk about the economics of health. In the 1950s, the “TV Dinner” was marketed as a miracle of modern convenience. It changed the way families ate, prioritizing speed over nutrition. Today, healthy, whole foods like fresh salmon and organic greens are significantly more expensive than a box of highly processed cereal. GLP-1s are currently a luxury for the upper-middle class. Until we address the fact that it is cheaper to eat poorly than it is to eat well, the “elimination” of obesity will remain a dream reserved for those with the best insurance plans.

Anhedonia

There is a psychological component often called “Anhedonia,” or the loss of pleasure. For many people, food is their primary source of joy, social connection, and comfort. GLP-1s work by making food seem unappealing. I’ve spoken with people who say they “miss wanting food.” They sit at a Thanksgiving dinner and feel nothing but a mild sense of nausea. Over years, this can lead to a sense of social isolation. If you can’t enjoy a meal with friends, a core part of the human experience is diminished, leading many to quit the drug just to feel “human” again.

​The global scale of the problem is also staggering. There are roughly 1 billion people worldwide living with obesity. To “eliminate” the disease, you would need to manufacture, ship, and refrigerate trillions of doses of these drugs. Think about the struggle to distribute the COVID-19 vaccine globally. Now imagine doing that every single month, forever, for a seventh of the world’s population. The logistics alone make “elimination” via medication a mathematical impossibility for the foreseeable future.

We also have to consider “Non-responders.” Just as some people can drink five cups of coffee and go straight to sleep, some people take maximum doses of Ozempic and lose zero pounds. Their bodies simply don’t process the GLP-1 hormone in the standard way. If we rely solely on these drugs, we leave behind millions of people whose biology doesn’t fit the “average” model. For them, the “miracle cure” is a frustrating expensive failure.

The Cobra Effect?

​There is also the historical lesson of “The Cobra Effect.” In colonial India, the government offered a bounty for dead cobras to reduce the population. In response, people started breeding cobras to kill them and collect the money. Sometimes, a solution creates a new problem. With GLP-1s, the “Cobra Effect” might be a total neglect of lifestyle education. If parents believe a shot can fix everything, they may stop teaching children how to cook or the importance of daily play, leading to an even less healthy next generation.

​Take the case study of gastroparesis. Some patients on these drugs develop “stomach paralysis,” where the stomach stops moving food along entirely. It is a rare but terrifying side effect. As these drugs move from being used by thousands to being used by millions, we will see more of these “one-in-a-million” tragedies. A drug that works for most but causes permanent damage to a few will always face regulatory and legal hurdles that prevent it from being a universal solution.

The pharmaceutical supply chain is another bottleneck. Last year, there were massive shortages of these drugs because the “pens” used to inject them couldn’t be manufactured fast enough. This created a “gray market” of compounded versions that weren’t always safe. When a “cure” depends on a complex plastic delivery device, it is vulnerable. If a factory in one part of the world shuts down, millions of people suddenly face a massive hormonal crash as their bodies search for a medication they can no longer find.

Fat But Fit?

​We should also look at the “Fat-But-Fit” paradox. Some people carry extra weight but have perfect blood sugar and cardiovascular health. By focusing entirely on weight loss via GLP-1s, we risk over-medicalizing people who are actually healthy. Historically, we have used Body Mass Index (BMI) as a blunt tool, but it doesn’t account for bone density or muscle. Forcing everyone into a “thin” mold with drugs might actually do more harm than good for those whose bodies are naturally larger but metabolically sound.

The marketing influence is another factor. Pharmaceutical companies are businesses; they want “chronic” patients—people who take the drug for life. They have little incentive to fund research into how people can successfully get off the drug and maintain their weight through lifestyle. This creates a loop where the “cure” becomes a subscription service. You don’t eliminate a disease if you just turn it into a lifelong monthly payment.

Stress Eating?

​Think about the “Anecdote of the Stress-Eater.” Sarah eats because her job is high-pressure and her marriage is failing. The GLP-1 shuts off her hunger, so she stops eating. But her stress has nowhere to go. Without her primary coping mechanism, she might turn to alcohol or other habits. This is known as “transfer addiction.” If we don’t treat the mind and the soul alongside the gut, the “weight” just moves from the body to another part of a person’s life.

​In the 1990s, the drug Fen-Phen was hailed as the end of obesity. People lost weight rapidly and felt amazing. Then, it was discovered that the drug was causing fatal heart valve damage. It was pulled from the shelves, and millions gained the weight back instantly. While GLP-1s appear much safer, we don’t have 30 years of data on what they do to the human body when taken continuously. Caution is a historical necessity.

Finally, there is the issue of cultural shift. True elimination of a health crisis requires a change in what we value. If we value “hustle culture” and “convenience” over slow meals and physical rest, obesity will always find a way back in. We can’t medicate our way out of a culture that hates the very things that keep us healthy. The drugs are a bridge, but we still haven’t decided what we want to build on the other side.

Conclusion

​In conclusion, GLP-1s are a brilliant tool, perhaps the best we’ve ever had. But like a hammer, they can’t build a house alone. We need the “lumber” of better food policy, the “nails” of urban exercise spaces, and the “blueprints” of mental health support. Until we have all the parts, obesity will remain a complex part of the human story, managed by medicine but not erased by it.